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Abstract
Background: The systematic vaccination with 23-valent polysaccharide pneumococcal vaccine
(PPV) was introduced as a strategic objective of health for all the people over 65 in Catalonia in
1999. We analysed the evolution of the pneumococcal vaccination rates from 2000 to 2003.
Methods: We conducted a retrospective population-based study including all the individuals 65
years or older assigned to 8 Primary Care Centres (PCCs) in Tarragona (Catalonia, Spain), who
figured in the administrative population databases on 31 December 2003 (n = 10,410 persons). We
assessed whether every person had received PPV during the last four years (2000 to 2003) or
whether they had received it before January 2000. Data sources were the computerised clinical
records of the 8 participating PCCs, which included adult vaccination registries and diagnoses
coded of International Classification of Diseases 9th Review
Results: The overall vaccination uptake increased to 38.6% at the end of 2000. Global accumulated
coverages increased more slowly the following years: 44.4% in 2001, 50.9% in 2002, and 53.1% at
the end of 2003. Vaccine uptake varied significantly according to age (46.7% in people 65–74 years-
old, 60.9% in people 75 years or more; p < 0.001) and number of diseases or risk factors (DRFs)
for pneumonia (47.1% vaccinated in people without DRFs, 56.8% in patients with one DRF, and
62.2% in patients with two or more DRFs; p < 0.001). The highest coverages were observed among
those patients with: diabetes (65.9%), active neoplasia (64.8%), history of stroke (63.7%), and
chronic lung disease (63.5%). The lowest uptake was observed among smokers (48.7%).
Discussion: The pneumococcal vaccination coverage increased quickly after the introduction of
the recommendation for free vaccination in all the elderly people (with and without risk factors),
but two years after the improvement the coverage became stable and increased slowly.
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Infections caused by Streptococcus pneumoniae are an
important cause of morbidity and mortality in the elderly,
especially in those with chronic diseases [1]. The 23-
valent polysaccharide pneumococcal vaccine (PPV) has
been available since 1983 and is currently recommended
for use in the elderly and high risk groups. More than 20
years later, despite many clinical trials and observational
studies on this vaccine, its effectiveness is controversial.
Several observational trials have shown a protective effect
in preventing pneumococcal bacteraemia, but others have
not shown this effect.
Meta analyses carried out regarding this vaccine are not
conclusive [2-5]. The last published Cochrane review con-
cluded that the PPV may not be effective to prevent pneu-
monia, but the vaccine has shown an efficacy of at least
53% to prevent pneumococcal invasive disease [6]. Now-
adays many advisory committees on immunisation prac-
tices recommend the use of PPV in high risk groups and
individuals over the age of 65 years on the basis that the
effectiveness of PPV in preventing pneumococcal bacter-
aemia among the elderly and high risk adults has been
demonstrated in observational studies. The vaccination is
cost-effective and there is sufficient evidence to justify its
widespread use [7-9].
In Spain, pneumococcal vaccination is not uniformly rec-
ommended in all the Spanish Autonomous Regions. In
Catalonia, a region in the northeast of Spain with a popu-
lation of 6 million people, a nationwide pneumococcal
vaccination program for all people 65 years or older (with
or without risk factors) began in October 1999. Before this
date PPV only was prescribed in hospital or outpatient vis-
its for high-risk subjects, and pneumococcal vaccination
coverage was 5.8% among our general elderly population
[10].
In the present study, we assessed the evolution of pneu-
mococcal vaccination coverage from 2000 to 2003 in the
general elderly population.
Methods
We conducted a retrospective, multicentred population-
based study located in The Primary Care Service of Tarra-
gona (Catalonia, Spain).
In the Spanish Health Care System, all persons are
assigned to one Primary Care Centre (PCC) and a General
Practitioner. All relevant medical details are filed on
patients from primary care visits, immunisations, medical
prescriptions, laboratory tests, hospital admissions, and
visits to outpatient clinics. In Catalonia all individuals are
also assigned to a PCC. In the Health District of Tarragona
(an urban area), the Catalonian Health Institute have 12
PCCs with an overall assigned population of 134,232
inhabitants (19 833 persons 65 years or older).
We included in the present study all the persons aged 65
years or older, who are assigned to 8 of the 12 PCCs and
who had at least 1 year of recorded database history prior
to the start of the survey to determine medical conditions
and vaccination status. The eligible population thus
included 10,410 persons 65 yrs or older on December 31,
2003, of which 4481 were male and 5929 female, with a
median age of 74.6 yrs (SD: 7.5). The mean age of eligible
subjects in 8 participating PCC ranged between 73.6 and
75.7 years-old.
The selection of the 8 participating PCCs was not ran-
domised and they were chosen taking into account the
existence of electronic clinical registries working since
1998 or before. The other 4 PCCs of the Health District of
Tarragona were not included because they only intro-
duced computerised clinical records more recently.
We assessed whether every eligible person had received
the pneumococcal vaccine during the last four years (from
Jan 1, 2000 to Dec 31, 2003) or whether they had received
it before January 2000. The pneumococcal vaccination
program was executed by PCCs and the vaccine used was
a 23-valent polysaccharide pneumococcal vaccine (PPV).
General Practitioners and Primary Care Nurses registered
the vaccination date in the electronic medical record.
Data sources were the computerised clinical records of the
8 participating PCCs, which included adult vaccination
registries and diagnosis code of international Classifica-
tion Diseases 9th Review (ICD-9). We considered as hav-
ing been correctly vaccinated those people who had the
PPV specific code registered, together with the date of
administration in their clinical record. We also considered
in each individual the presence or absence of any code
(ICD-9) of the following diseases or risk factors (DRF) for
pneumonia: diabetes mellitus, chronic heart disease,
chronic lung disease, smoking, history of stroke, chronic
nephropathy, chronic liver disease, excessive consump-
tion of alcohol, active neoplasia and immunocompro-
mised status.
Vaccine coverages were calculated according to age-
groups, sex and presence of DRFs. The statistical differ-
ences between vaccine coverages were evaluated using the
differences between the percentages. Odds ratio (OR)
were used to evaluate the association between the recep-
tion of pneumococcal vaccine and the presence of each
DRF. All results were expressed with 95% confidence
intervals (CIs).Page 2 of 6
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Catalonian Health Institute (expedient FIS PI021117) and
was conducted in accordance with the general the general
principles for observational studies.
Results
The overall pneumococcal vaccine coverage increased to
38.6% at the end of the first year after the implementation
of the systematic recommendation to receive the PPV in
all elderly individuals. The overall accumulative coverages
increased more slowly in the following years: 44.4% in
2001, 50.9% in 2002, and 53.1% in 2003. At the end of
2003, pneumococcal vaccine coverages ranged from
44.9% to 66.3% in 8 participating PCCs.
The greater number of pneumococcal vaccines were
administered during influenza vaccination campaigns.
63.2% of PPV was administered in October and Novem-
ber, 23.6% of PPV was administered during the cold
months (December-April) and 13.2% during the warm
months (May-September).
At the end of 2003, pneumococcal vaccine coverages var-
ied significantly according to age: 46.7% (95% CI: 45.5–
48.0) among people 65–74 years-old, and 60.9% (95%
CI: 58.9–61.8) among people 75 years or older (p <
0.001). The vaccination coverage was 53.4% (95% CI:
51.9–54.9) in males and 52.7% (95% CI: 51.4–54.0) in
females (p = 0.481). The vaccination coverages in Decem-
ber 2003 according to age and gender are shown in Table
1.
The evolution of vaccination coverages during the four
years of the survey, according to the presence of diseases
or risk factors (DRF) for pneumonia are shown in Table 2.
At the end of the survey, we observed higher PPV cover-
ages among those patients with diabetes (65.9%), active
malignancy (64.8%), history of stroke (63.7%), and
chronic lung disease (63.5%). The lowest PPV rates were
observed among smokers (48.7%), drinkers (54.5%) and
patients with chronic liver disease (53.1%).
We observed a significant increase of pneumococcal vacci-
nation coverage according to the number of DRFs for
pneumonia: 47.1% vaccinated among those without DRF,
56.8% among those with one DRF, and 62.2% among
those with two or more DRFs for pneumonia (p < 0.001).
Table 3 shows pneumococcal vaccination coverage in the
study population at the end of 2003 according to the pres-
ence or absence of each disease or risk factor for pneumo-
nia. Except in three conditions (chronic liver disease,
consumption of alcohol and smoking) the pneumococcal
vaccine coverages were significantly higher among those
patients who had a DRF in comparison to those who did
not have a DRF.
Discussion
The 23-valent polysaccharide pneumococcal vaccine
(PPV) for the elderly population has been recommended
in some developed countries for more than a decade. Nev-
ertheless, despite the time that has elapsed, achieving a
high population uptake has proven to be difficult [11-14].
In Catalonia the recommendation for systematic pneu-
mococcal vaccination in the general elderly population
was introduced at the end of 1999 as an objective for all
the Primary Care Centers (PCC) of the Catalonian Health
Service. Before this date, the prescription of pneumococ-
cal vaccination was only possible in hospital or during a
visit to a specialist clinics for high risk subjects (diabetes,
chronic heart or lung disease, and inmunocompromised
subjects). Before starting the vaccination program, pneu-
mococcal vaccination coverage reached about 6% among
our general elderly population [10]. We analysed the evo-
lution of pneumococcal vaccine uptake since December
2000 to December 2003. During this period of time no
specific campaign was carried out, and the invitation for
pneumococcal vaccination was offered when the elderly
subjects (with or without risk factors) came to the PCCs
during the influenza vaccination campaigns or in any
other visit throughout the rest of the year.
In our study population, the vaccination coverage
increased quickly after the introduction of the recommen-
dation for free vaccination in all the elderly people (from
6% at the beginning of 2000 to 44% at the end of 2001).
But two years later the improvement of coverage became
slow (51% in 2002 and 53% in 2003).
Although the sample was wide (more than 10,400 elderly
individuals), all the persons belong to one of 8 PCCs
located in the district of Tarragona. This could be a prob-
lem if the results were to be extrapolated exactly to the
whole of Catalonia. The 8 PCCs included in our study
were not randomised. They were chosen because their
computerised data registers had been working for more
than 6 years and they represented the 12 PCCs of the dis-
trict of Tarragona.
Although 8 participating PCCs had electronic registries
working before starting the program, it is possible that
some vaccinations given prior to the existence of the com-
puterized registries would not have been recorded in the
current computerized system.
We think that our current coverage (53%) can be consid-
ered low, this was achieved four years after the introduc-
tion of the recommendation for systematic pneumococcalPage 3 of 6
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65–74 year olds could be due in part to a limited oppor-
tunity for persons turning 65 to have received the pneu-
mococcal vaccine. Age was calculated by age at the end of
the year and consequently persons who turned 65 near
the end of the year had little opportunity to receive the
PPV.
In order to evaluate our results, it must be known that in
Spain, the medical care is a publically funded service for
all the population and most prescriptions (including
PPV) are free for people over 65 years (there is a 60% dis-
count for people under 65 yrs) and this gives an important
difference when comparing vaccination uptakes with
other countries where medical care and prescriptions need
to be paid, totally or partially, directly or through a private
medical insurance.
The vaccination coverages in developed countries where
PPV use has been recommended for a longer period of
time are about 50% to 65% in the overall elderly popula-
tion [11-14]. We think that the doubts about the effective-
ness of PPV could have influenced clinical practice and
this could have been the reason why a higher coverage
with PPV was not reached. Primary Care physicians (they
are the principal promoters of the vaccination) should be
made aware that although meta analyses carried out about
this vaccine were not conclusive, this does not mean that
the vaccine is not effective, since several observational
studies have proven its efficacy and cost-effectiveness in
preventing invasive pneumococcal disease.
A meta-analysis limited to studies in more developed
countries showed a protective effect to prevent pneumo-
coccal bacteraemia but did not find a significant protec-
tive effect against pneumonia among elderly subjects or
high-risk groups [5]. A recent Cochrane review [6] con-
cluded that, while polysaccharide pneumococcal vaccines
do not appear to reduce the incidence of pneumonia or
death in elderly people (with or without chronic dis-
eases), the evidence from non-randomised studies sug-
gests that the vaccines are effective in reducing the
incidence of the more specific outcome (invasive pneu-
mococcal disease) among adults and immunocompetent
Table 2: Evolution of pneumococcal vaccination coverages from 2000 to 2003 in people 65 years or older in Tarragona (Catalonia, 
Spain) according to the presence of certain diseases or risk factors (DRF) for pneumonia.
VARIABLES 2000 2001 2002 2003
% % % % (95% CI)
Chronic lung disease 48.1 54.2 61.5 63.5 (60.8–66.2)
Diabetes mellitus 45.1 51.2 58.4 65.9 (64.0–67.8)
Active neoplasia 43.1 56.7 62.1 64.8 (59.3–70.3)
Immunocompromise 47.1 55.0 61.3 63.1 (60.6–65.6)
Chronic heart disease 47.7 53.5 60.4 63.0 (60.4–65.6)
Chronic nephropathy 48.5 55.3 60.2 62.7 (58.0–67.4)
Stroke 45.5 52.9 62.1 63.7 (58.5–68.9)
Chronic liver disease 36.7 46.5 52.1 53.1 (46.6–59.6)
Drinkers 36.3 43.6 50.8 54.5 (48.8–60.2)
Smokers 32.2 38.9 46.6 48.7 (45.6–51.8)
Level of risk for pneumonia
None DRF 33.9 38.9 45.1 47.1 (45.8–48.4)
One DRF 41.9 47.9 54.6 56.8 (55.1–58.5)
Two or more DRF 45.5 52.6 60.3 62.2 (60.1–64.3)
Overall population 38.6 44.4 50.9 53.1 (52.2–54.9)
Table 1: Pneumococcal vaccination coverages at the end of 2003 in people 65 years or older in Tarragona (Catalonia, Spain) according 
to age groups and gender.
Gender Male Female Difference (male-female) Overall population
Age groups % % % (95% CI) P-value % (95% CI)
65–69 yrs (n = 3189) 37.5 41.1 -3.6 (-7.0 to -0.2) 0.040 39.3 (37.6 to 41.0)
70–74 yrs (n = 2814) 55.8 54.4 1.4 (-2.5 to 5.3) 0.453 55.1 (53.3 to 56.9)
75–79 yrs (n = 2183) 65.9 57.3 8.6 (4.5 to 12.7) 0.001 61.6 (59.6 to 63.6)
80–84 yrs (n = 1335) 66.7 60.6 6.1 (0.7 to 11.5) 0.027 63.6 (60.8 to 66.4)
85–89 yrs (n = 609) 65.8 62.8 3.0 (-6.3 to 12.3) 0.469 64.3 (60.5 to 68.1)
90 or more yrs (n = 280) 54.5 54.6 -0.1 (-12.2 to 12.0) 0.980 54.5 (48.7 to 60.3)
Overall (N = 10,410) 53.4 52.7 0.7 (-1.2 to 2.6) 0.481 53.1 (52.2 to 54.9)Page 4 of 6
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published meta-analysis, Melegaro[15] concluded that
the PPV provides 65% protection against invasive pneu-
mococcal disease in the general elderly population, hav-
ing a moderate 20% effect in the high risk elderly. They
also concluded that the vaccine could have a little or null
effect against pneumonia in the general elderly popula-
tion (-20% to 16%). In a recent review published in 2004,
Fedson and Liss concluded that the PPV is effective in pre-
venting pneumococcal bacteraemia and invasive pneu-
mococcal disease, the vaccination is cost-effective, and
they recommend the vaccination in high-risk individuals
and the overall elderly population [16].
In USA the current uptakes are about 60% in the general
elderly population [11,12]. In Stockholm County (Swe-
den), an interventionist vaccination program (with a low
cost PPV, support of the media and mailing individually
to all the population over 65) achieved only a 37% of cov-
erage in 2 years (1998–99) [13]. In Victoria (Australia) the
PPV coverage among people 65 years or older increased
from 7% in 1997 to 51% in 2000 after a publically funded
pneumococcal vaccination program among all the elderly
population [14].
Our study shows that once the mid range vaccination rates
are reached, they are hard to improve, even with a free vac-
cine.
During the four years of the survey, no specific PPV cam-
paign was carried out and the strategy used for the vacci-
nation was done in an opportunistic way. We believe that
this strategy probably was not very efficient, since the vac-
cination rates reached in elderly people with high risk
were only slightly more than in those with low risk.
Although the last published meta-analysis[15] concluded
that the vaccine must be less effective among the popula-
tion at high-risk of suffering from pneumonia, this is a
controversial aspect. We think that these high-risk individ-
uals could have received more benefit from the vaccina-
tion because the incidence of pneumococcal infection is
higher in comparison with low-risk groups [17].
The vaccine coverages in several countries are compared
with difficulty due to the different characteristics of each
National Health Service. Our study contributes valuable
information to know and to compare the evolution of
pneumococcal vaccine coverages in a European Region
where a free PPV has been offered to all elderly people
(with or without risk factors) since the end of 1999.
Although there weren't any guidelines recommending the
simultaneous administration of pneumococcal and influ-
enza vaccines in our country, we observed that there was
a correlation between both; since almost 63% of PPV were
administrated in our study population during the influ-
enza vaccination campaigns. A pneumococcal vaccine
coverage of 90% has been recently set as an objective in all
the subjects aged 65 or older by the Center for Disease
Control for 2010 [12]. We think that Influenza vaccina-
tion campaigns can be a good opportunity to attract those
who have not had the PPV. Some studies have shown that
there is an additive effect between both vaccines [13,18].
This strategy could be good to increase significantly the
PPV coverage.
We believe that some work has to be done to reduce the
existing doubts about the effectiveness of the PPV among
the health professionals. It is true that there is no docu-
mented evidence of an effect of this vaccine on mortality
rates in many developed countries; but it would be desir-
able that similar levels of evidence were required for many
other recommended preventive measures, and in particu-
lar for therapies that are commonly used.
Table 3: Pneumococcal vaccination coverages at December 31, 2003 according to the presence or absence of certain diseases or risk 
factors (DRF) for pneumonia among people 65 years or older in Tarragona (Catalonia, Spain).
VARIABLES Percent vaccinated among those 
with DRF
Percent vaccinated among those 
without DRF
Odds Ratio*
% (95% CI) % (95% CI) OR (95%CI) P-value
Chronic lung disease 63.5 (60.8–66.2) 51.8 (50.8–52.8) 1.57 (1.38–1.79) <0.001
Diabetes mellitus 65.9 (64.0–67.8) 49.6 (48.5–50.7) 1.52 (1.38–1.67) <0.001
Active neoplasia 64.8 (59.3–70.3) 52.8 (51.8–53.8) 1.62 (1.24–2.10) <0.001
Immunocompromise 63.1 (60.6–65.6) 51.7 (50.7–52.7) 1.56 (1.38–1.76) <0.001
Chronic heart disease 63.0 (60.4–65.6) 51.8 (50.8–52.8) 1.48 (1.30–1.68) <0.001
Chronic nephropathy 62.7 (58.0–67.4) 52.7 (51.8–53.7) 1.37 (1.11–1.71) 0.004
Stroke 63.7 (58.5–68.9) 52.8 (51.8–53.7) 1.41 (1.11–1.80) 0.005
Chronic liver disease 53.1 (46.6–59.6) 53.1 (52.1–54.1) 0.96 (0.72–1.29) 0.812
High alcohol consumption 54.5 (48.8–60.2) 53.1 (52.1–54.1) 1.13 (0.88–1.46) 0.319
Smoking 48.7 (45.6–51.8) 53.5 (52.5–54.5) 0.87 (0.75–1.01) 0.073
*Odds Ratio (OR) were calculated for those people who received the pneumococcal vaccination.Page 5 of 6
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The pneumococcal vaccination coverage increased quickly
after the introduction of the recommendation for free vac-
cination in all the elderly people (with and without risk
factors), but two years after the improvement the coverage
became stable and increased slowly. Our study shows that
once the acceptable vaccination rates are reached, they are
hard to improve, even with a free vaccine.
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